British COVID-19 Vaccine Creates Strong Immune Response in Early Clinical Trials

A potential coronavirus vaccine called ChAdOx1 nCoV-19 (AZD1222) appears to create a strong immune response in a large early-stage human trial, according to the medical journal The Lancet.

The possible vaccine is developed by Oxford University with pharmaceutical giant AstraZeneca, both in the UK, which has been demonized for years by Republicans for having “socialist medicine,” reports CNBC.

Oxford professor Andrew Pollard explained the science behind the vaccine in a press release (which will likely be ignored by half of all Americans who have no interest, or basic education, in science):

The immune system has two ways of finding and attacking pathogens — antibody and T cell responses. This vaccine is intended to induce both, so it can attack the virus when it’s circulating in the body, as well as attacking infected cells. We hope this means the immune system will remember the virus, so that our vaccine will protect people for an extended period.

NBC News notes the clinical trial did not see if the vaccine prevents coronavirus infection, which will be answered in other clinical trials that are underway.

(Sources: CNBC, The Lancet, NBC News)

You might be interested in

LEAVE YOUR COMMENT

Your email address will not be published. Required fields are marked *

Get the latest breaking news video clips before everyone else with our newsletter! We do not share or sell your email address with anyone.